BITUMENS AND BITUMEN EMISSIONS, AND SOME N- AND S-HETEROCYCLIC POLYCYCLIC AROMATIC HYDROCARBONS

VOLUME 103

This publication represents the views and expert opinions of an IARC Working Group on the Evaluation of Carcinogenic Risks to Humans, which met in Lyon, 11-18 October 2011

LYON, FRANCE - 2013

IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS
## CONTENTS

### NOTE TO THE READER

### LIST OF PARTICIPANTS

### PREAMBLE

A. GENERAL PRINCIPLES AND PROCEDURES
   1. Background
   2. Objective and scope
   3. Selection of agents for review
   4. Data for the Monographs
   5. Meeting participants
   6. Working procedures

B. SCIENTIFIC REVIEW AND EVALUATION
   1. Exposure data
   2. Studies of cancer in humans
   3. Studies of cancer in experimental animals
   4. Mechanistic and other relevant data
   5. Summary
   6. Evaluation and rationale

### GENERAL REMARKS

### BITUMENS AND BITUMEN EMISSIONS

1. Exposure Data
   1.1 Identification of the agent: definitions and classifications
   1.2 Methods of analysis
   1.3 Production and use
   1.4 Occurrence and exposure
   1.5 Regulations and guidelines

2. Cancer in Humans
   2.1 Introduction
   2.2 Cohort studies
   2.3 Case–control studies
   2.4 Meta-analyses

3. Cancer in Experimental Animals
   3.1 Mouse
3.2 Rat ................................................................. 153
3.3 Rabbit ............................................................. 154
3.4 Guinea-pig ......................................................... 155
4. Mechanistic and Other Relevant Data ............................................... 155
  4.1 Overview of the mechanisms of carcinogenesis of PAHs .......................... 155
  4.2 Absorption, distribution, metabolism, and excretion of bitumens and bitumen fume ........ 164
  4.3 Genetic and related effects ............................................................... 170
  4.4 Other effects relevant to carcinogenesis .............................................. 189
  4.5 Mechanistic considerations ............................................................... 193
5. Summary of Data Reported ................................................................... 196
  5.1 Exposure data .................................................................................. 196
  5.2 Human carcinogenicity data .............................................................. 197
  5.3 Animal carcinogenicity data .............................................................. 200
  5.4 Mechanistic and other relevant data .................................................. 202
6. Evaluation ......................................................................................... 203
  6.1 Cancer in humans .............................................................................. 203
  6.2 Cancer in experimental animals ......................................................... 203
  6.3 Mechanistic and other relevant data .................................................. 203
  6.4 Overall evaluation ............................................................................. 204
  6.5 Rationale ......................................................................................... 204
References .............................................................................................. 204

SOME N- AND S-HETEROCYCLIC POLYCYCLIC AROMATIC HYDROCARBONS ............... 221
1. Exposure Data .................................................................................. 221
  1.1 Identification of the agents ............................................................... 221
  1.2 Analysis .......................................................................................... 225
  1.3 Production and use ......................................................................... 226
  1.4 Occurrence and exposure .............................................................. 226
  1.5 Regulations and guidelines ............................................................. 229
2. Cancer in Humans .............................................................................. 229
3. Cancer in Experimental Animals ......................................................... 229
  3.1 Benz[a]acridine .............................................................................. 229
  3.2 Benz[c]acridine .............................................................................. 230
  3.3 Dibenzo[a,h]acridine ...................................................................... 235
  3.4 Dibenzo[a,j]acridine ................................................................. 241
  3.5 Dibenzo[c,h]acridine ...................................................................... 246
  3.6 Carbazole .................................................................................... 248
  3.7 7H-Dibenzo[c,g]carbazole ............................................................. 252
  3.8 Dibenzothiophene ......................................................................... 257
  3.9 Benzo[b]naphtho[2,1-d]-thiophene .................................................... 257
4. Mechanistic and Other Relevant Data ................................................. 258
  4.1 Benz[a]acridine .............................................................................. 258
  4.2 Benz[c]acridine .............................................................................. 260
  4.3 Dibenzo[a,h]acridine ..................................................................... 262
  4.4 Dibenzo[a,j]acridine ................................................................. 266
  4.5 Dibenzo[c,h]acridine ..................................................................... 271
<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>4.6 Carbazole</td>
<td>274</td>
</tr>
<tr>
<td>4.7 7H-Dibenzo[c,g]carbazole</td>
<td>275</td>
</tr>
<tr>
<td>4.8 Dibenzo[cd]carbazole</td>
<td>275</td>
</tr>
<tr>
<td>4.9 Benzo[b]naphtho[2,1-d]thiophene</td>
<td>283</td>
</tr>
<tr>
<td>5. Summary of Data Reported</td>
<td>285</td>
</tr>
<tr>
<td>5.1 Exposure data</td>
<td>285</td>
</tr>
<tr>
<td>5.2 Human carcinogenicity data</td>
<td>285</td>
</tr>
<tr>
<td>5.3 Animal carcinogenicity data</td>
<td>285</td>
</tr>
<tr>
<td>5.4 Mechanistic and other relevant data</td>
<td>287</td>
</tr>
<tr>
<td>6. Evaluation</td>
<td>292</td>
</tr>
<tr>
<td>6.1 Cancer in humans</td>
<td>292</td>
</tr>
<tr>
<td>6.2 Cancer in experimental animals</td>
<td>292</td>
</tr>
<tr>
<td>6.3 Overall evaluation</td>
<td>292</td>
</tr>
<tr>
<td>References</td>
<td>292</td>
</tr>
</tbody>
</table>

GLOSSARY ..................................................................................................................305

LIST OF ABBREVIATIONS .............................................................................................309

CUMULATIVE CROSS INDEX TO IARC MONOGRAPHS .....................................................311
NOTE TO THE READER

The term ‘carcinogenic risk’ in the IARC Monographs series is taken to mean that an agent is capable of causing cancer. The Monographs evaluate cancer hazards, despite the historical presence of the word ‘risks’ in the title.

Inclusion of an agent in the Monographs does not imply that it is a carcinogen, only that the published data have been examined. Equally, the fact that an agent has not yet been evaluated in a Monograph does not mean that it is not carcinogenic. Similarly, identification of cancer sites with sufficient evidence or limited evidence in humans should not be viewed as precluding the possibility that an agent may cause cancer at other sites.

The evaluations of carcinogenic risk are made by international working groups of independent scientists and are qualitative in nature. No recommendation is given for regulation or legislation.

Anyone who is aware of published data that may alter the evaluation of the carcinogenic risk of an agent to humans is encouraged to make this information available to the Section of IARC Monographs, International Agency for Research on Cancer, 150 cours Albert Thomas, 69372 Lyon Cedex 08, France, in order that the agent may be considered for re-evaluation by a future Working Group.

Although every effort is made to prepare the Monographs as accurately as possible, mistakes may occur. Readers are requested to communicate any errors to the Section of IARC Monographs, so that corrections can be reported in future volumes.